{"entity":{"id":"nct07437287","kind":"trial","name":"Testing Mitazalimab in Combination With Standard Chemotherapy in Immunotherapy Resistant Advanced Biliary Tract Cancers","aka":["CROCOBIL"],"tldr":"A phase 2/3 trial of FOLFOX in gallbladder cancer and other biliary tract cancers, run by UNICANCER, not yet recruiting.","summary":"Testing Mitazalimab in Combination With Standard Chemotherapy in Immunotherapy Resistant Advanced Biliary Tract Cancers is a phase 2/3, randomised interventional study registered as NCT07437287 by UNICANCER, with a registry enrolment figure of 160 participants, started 2026-07 and due to reach its primary completion in 2030-04. Interventions recorded: mFOLFOX regimen, Mitazalimab. Conditions listed: Biliary Tract Cancer (BTC). Gallbladder cancer is named in the registry entry: \"2. Histologically-proven intrahepatic cholangiocarcinoma, extrahepatic (perihilar/distal) cholangiocarcinoma, or gallbladder carcinoma (ampullary carcinoma excluded)\". Sites: France. No results are recorded here; the registry entry is the source.","status":"planned","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT07437287","url":"https://clinicaltrials.gov/study/NCT07437287"}],"tags":["ctgov-ingest","gallbladder-deep-dive"],"related":[],"cancers":["gallbladder","cholangiocarcinoma","intrahepatic-cholangiocarcinoma","extrahepatic-cholangiocarcinoma","biliary-tract-cancer","ampullary"],"sections":[],"technologies":["cytotoxic-chemotherapy","platinum"],"targets":[],"drugs":["folfox"],"companies":["unicancer"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07437287","phase":"2/3","setting":"Countering Immunotherapy Resistance With Novel Combinations in Advanced Biliary Tract Cancers","sponsor":"UNICANCER","participation":[{"nct":"NCT07437287","source":"https://clinicaltrials.gov/study/NCT07437287","fetchedAt":"2026-10-07T16:55:44.977Z","studySha256":"967201d1d8bd4aa21e8bd802b3fc2ad17152a29c3d2be90bfd9d544fe147d630","overallStatus":"NOT_YET_RECRUITING","lastUpdatePosted":"2026-02-27","leadSponsor":"UNICANCER","collaboratorCount":1,"minimumAge":"18 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":160,"enrolmentType":"ESTIMATED","siteCount":22,"recruitingSiteCount":0,"countries":["France"]}],"started":"2026-07","startedType":"estimated","enrolled":160,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07437287/","neighbours":{"cancer":[{"id":"ampullary","kind":"cancer","name":"Ampullary cancer (ampulla of Vater)","route":"/cancers/ampullary/"},{"id":"biliary-tract-cancer","kind":"cancer","name":"Biliary tract cancer (all types)","route":"/cancers/biliary-tract-cancer/"},{"id":"cholangiocarcinoma","kind":"cancer","name":"Biliary tract cancer (cholangiocarcinoma)","route":"/cancers/cholangiocarcinoma/"},{"id":"extrahepatic-cholangiocarcinoma","kind":"cancer","name":"Extrahepatic cholangiocarcinoma (perihilar and distal)","route":"/cancers/extrahepatic-cholangiocarcinoma/"},{"id":"gallbladder","kind":"cancer","name":"Gallbladder cancer","route":"/cancers/gallbladder/"},{"id":"intrahepatic-cholangiocarcinoma","kind":"cancer","name":"Intrahepatic cholangiocarcinoma","route":"/cancers/intrahepatic-cholangiocarcinoma/"}],"technology":[{"id":"cytotoxic-chemotherapy","kind":"technology","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/"},{"id":"platinum","kind":"technology","name":"Platinum agents","route":"/technologies/platinum/"}],"drug":[{"id":"folfox","kind":"drug","name":"FOLFOX (5-FU, leucovorin, oxaliplatin)","route":"/drugs/folfox/"}],"company":[{"id":"unicancer","kind":"company","name":"UNICANCER","route":"/companies/unicancer/"}],"term":[{"id":"gallbladder-cancer-in-biliary-trials","kind":"term","name":"Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups)","route":"/terms/gallbladder-cancer-in-biliary-trials/"}]}}